Dyslipidemia - Pipeline Review, H1 2020

March 2020 | 372 pages | ID: D6CF6F979F0EN
Global Markets Direct

Abstracts

Dyslipidemia - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2020, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the 'bad' low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the 'good' high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 26, 19, 25, 34, 7 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Dyslipidemia - Overview
Dyslipidemia - Therapeutics Development
Dyslipidemia - Therapeutics Assessment
Dyslipidemia - Companies Involved in Therapeutics Development
Dyslipidemia - Drug Profiles
Dyslipidemia - Dormant Projects
Dyslipidemia - Discontinued Products
Dyslipidemia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dyslipidemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Dyslipidemia - Pipeline by 89bio Inc, H1 2020
Dyslipidemia - Pipeline by AbbVie Inc, H1 2020
Dyslipidemia - Pipeline by ABIONYX Pharma SA, H1 2020
Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2020
Dyslipidemia - Pipeline by AD Pharmaceuticals Co Ltd, H1 2020
Dyslipidemia - Pipeline by Yuhan Corp, H1 2020
Dyslipidemia - Dormant Projects, H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..2), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..3), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..4), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..5), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..6), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..7), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..8), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..9), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..10), H1 2020
Dyslipidemia - Dormant Projects, H1 2020 (Contd..11), H1 2020
Dyslipidemia - Discontinued Products, H1 2020
Dyslipidemia - Discontinued Products, H1 2020 (Contd..1), H1 2020
Dyslipidemia - Discontinued Products, H1 2020 (Contd..2), H1 2020
Dyslipidemia - Discontinued Products, H1 2020 (Contd..3), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dyslipidemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

89bio Inc
AbbVie Inc
ABIONYX Pharma SA
Acasti Pharma Inc
AD Pharmaceuticals Co Ltd
Affina Biotechnologies Inc
Afimmune Biopharma Ltd
Akcea Therapeutics Inc
Akeso Biopharma Inc
Amarin Corp Plc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
AVVA Pharmaceuticals AG
BCWorld Pharm Co Ltd
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Cardax Inc
Celon Pharma SA
Centaurus Therapeutics Inc
Centeer BioTherapeutics Ltd Co
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Corbus Pharmaceuticals Inc
Corvidia Therapeutics Inc
CVI Pharmaceuticals US Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delivra Corp
DongKoo Bio & Pharma Co Ltd
Eli Lilly and Co
Elyson Pharmaceutical Co Ltd
Esperion Therapeutics Inc
Gilead Sciences Inc
Golden Biotechnology Corp
Handok Inc
Hanlim Pharm Co Ltd
Hanmi Pharmaceuticals Co Ltd
Ildong Pharmaceutical Co Ltd
Inovio Pharmaceuticals Inc
InStar Technologies AS
Jeil Pharmaceutical Co Ltd
Jenrin Discovery Inc
Jiangsu Hengrui Medicine Co Ltd
Kolmar Pharma Co Ltd
Korea United Pharm Inc
Kotobuki Pharmaceutical Co Ltd
Kowa Co Ltd
Krisani Bio Sciences Pvt Ltd
Kuhnil Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
Kyung Dong Co Ltd
LG Chem Ltd
LipimetiX Development Inc
Matinas BioPharma Holdings Inc
MD Healthcare Inc
Micelle BioPharma Inc
Mochida Pharmaceutical Co Ltd
MYR GmbH
NeuroBo Pharmaceuticals Inc
Nippon Chemiphar Co Ltd
NorthSea Therapeutics BV
NovalGen Ltd
Novartis AG
NuSirt Biopharma Inc
Omeros Corp
OncoImmune Inc
Pfizer Inc
Pharmena SA
Regeneron Pharmaceuticals Inc
Reneo Pharmaceuticals Inc
Sequor Pharmaceuticals LLC
Shanghai Institute of Pharmaceutical Industry
Shanghai Junshi Bioscience Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shifa Biomedical Corp
SJT Molecular Research SL
Staten Biotechnology BV
Suzhou Ribo Life Sciences Co Ltd
Sveikatal Inc
Synokem Pharmaceuticals Ltd
Tetranov International Inc
Viking Therapeutics Inc
Yuhan Corp